Application of 199596-05-9 as antituberculous compound
The invention discloses application of 199596-05-9 as an anti-tuberculosis compound, a bacterial level inhibitor high-throughput screening model is established on the basis of MTB H37Rv (ATCC 27294), 7285 samples of a bioactive compound library L4000 are screened, the anti-tuberculosis compound 199596-05-9 is screened out, the inhibition and killing activity of the compound 199596-05-9 on MTB and NTM is verified through experiments, and the application of the compound 199596-05-9 as the anti-tuberculosis compound has the advantages that the inhibition and killing activity of the compound 199596-05-9 on the MTB and the NTM is improved; the application of the 199596-05-9 in the treatment of infectious diseases caused by MTB, especially drug-resistant MTB treatment and NTM infection is determined, so that the application of the 199596-05-9 as an anti-tuberculosis compound is expanded, and finally, the result that the 199596-05-9 is used as a novel high-efficiency and low-toxicity anti-tuberculosis drug is obtained..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Europäisches Patentamt - (2023) vom: 29. Sept. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
LIU HAN [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Sonstige Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-09-29, Last update posted on www.tib.eu: 2023-12-19, Last updated: 2023-12-22 |
|---|
| Patentnummer: |
CN116808035 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA018819540 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA018819540 | ||
| 003 | DE-627 | ||
| 005 | 20231222112803.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231222s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA018819540 | ||
| 035 | |a (EPA)CN116808035 | ||
| 035 | |a (EPA)88127756 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a LIU HAN |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Application of 199596-05-9 as antituberculous compound |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2023-09-29, Last update posted on www.tib.eu: 2023-12-19, Last updated: 2023-12-22 | ||
| 520 | |a The invention discloses application of 199596-05-9 as an anti-tuberculosis compound, a bacterial level inhibitor high-throughput screening model is established on the basis of MTB H37Rv (ATCC 27294), 7285 samples of a bioactive compound library L4000 are screened, the anti-tuberculosis compound 199596-05-9 is screened out, the inhibition and killing activity of the compound 199596-05-9 on MTB and NTM is verified through experiments, and the application of the compound 199596-05-9 as the anti-tuberculosis compound has the advantages that the inhibition and killing activity of the compound 199596-05-9 on the MTB and the NTM is improved; the application of the 199596-05-9 in the treatment of infectious diseases caused by MTB, especially drug-resistant MTB treatment and NTM infection is determined, so that the application of the 199596-05-9 as an anti-tuberculosis compound is expanded, and finally, the result that the 199596-05-9 is used as a novel high-efficiency and low-toxicity anti-tuberculosis drug is obtained. | ||
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a MENG JIANZHOU |4 aut | |
| 700 | 0 | |a PANG YU |4 aut | |
| 700 | 0 | |a LIU YISHUANG |4 aut | |
| 700 | 0 | |a LI PEI |4 aut | |
| 700 | 0 | |a WANG XIAO |4 aut | |
| 700 | 0 | |a WANG WEI |4 aut | |
| 700 | 0 | |a WANG HEYONG |4 aut | |
| 700 | 0 | |a LI XI |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 29. Sept. |
| 773 | 1 | 8 | |g year:2023 |g day:29 |g month:09 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/88127756/publication/CN116808035A1?q=CN116808035 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2023 |b 29 |c 09 |
| 951 | |a AR | ||
| 952 | |j 2023 |b 29 |c 09 | ||